UBS Maintains a 'Neutral' on THQ Inc. (THQI); Reorganization Results in Lowered Outlook
Get Alerts THQI Hot Sheet
Price: $0.31 --0%
Rating Summary:
0 Buy, 6 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 12 | Down: 21 | New: 20
Rating Summary:
0 Buy, 6 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 12 | Down: 21 | New: 20
Join SI Premium – FREE
UBS maintains a 'Neutral' on THQ Inc. (NASDAQ: THQI) price target cut from $1.00 to $0.60.
UBS analyst said, "THQI will stream line its organization and cost structure going forward, resulting in a smaller company as it exits the kids’ licensed game category (e.g. SpongeBob) and focuses on core games (e.g. Saints Row) and digital. THQ ended the qtr with $48MM cash and no borrowings against its $50MM revolver."
UBS slashes FY12 EPS loss from (0.42) to (1.77) and FY13 from (0.11) to (1.43).
For an analyst ratings summary and ratings history on THQ Inc. click here. For more ratings news on THQ Inc. click here.
Shares of THQ Inc. closed at $0.53 yesterday.
UBS analyst said, "THQI will stream line its organization and cost structure going forward, resulting in a smaller company as it exits the kids’ licensed game category (e.g. SpongeBob) and focuses on core games (e.g. Saints Row) and digital. THQ ended the qtr with $48MM cash and no borrowings against its $50MM revolver."
UBS slashes FY12 EPS loss from (0.42) to (1.77) and FY13 from (0.11) to (1.43).
For an analyst ratings summary and ratings history on THQ Inc. click here. For more ratings news on THQ Inc. click here.
Shares of THQ Inc. closed at $0.53 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Cullinan Oncology Inc. (CGEM) PT Raised to $27 at UBS
- Deutsche Bank Downgrades Workday (WDAY) to Hold
- Stifel on Bally's Corp (BALY): 'expect shares to continue to trade mainly on development project cost & financing updates'
Create E-mail Alert Related Categories
Analyst CommentsRelated Entities
UBSSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share